ReviewYearbook of medical informatics2018
The Omics Revolution Continues: The Maturation of High-Throughput Biological Data Sources.
Review in Yearbook of medical informatics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Molecular Profiling of Circulating Tumour Cells and Circulating Tumour DNA: Complementary Insights from a Single Blood Sample Utilising the ParsortixCurrent issues in molecular biology · 2024Review
- Domain loss enabled evolution of novel functions in the snake three-finger toxin gene superfamily.Nature communications · 2023Article
- Challenges and considerations for single-cell and spatially resolved transcriptomics sample collection during spaceflight.Cell reports methods · 2022Review
- Article
- -Omics potential of in vitro skin models for radiation exposure.Cellular and molecular life sciences : CMLS · 2022Review
- An equivalence test between features lists, based on the Sorensen-Dice index and the joint frequencies of GO term enrichment.BMC bioinformatics · 2022Article
- Fabrication approaches for high-throughput and biomimetic disease modeling.Acta biomaterialia · 2021Review
- Research status and prospects of biomarkers for nasopharyngeal carcinoma in the era of high‑throughput omics (Review).International journal of oncology · 2021Review
- Systems epidemiology and cancer: A review of the National Institutes of Health extramural grant portfolio 2013-2018.PloS one · 2021Review
- Comparison of commercially available whole-genome sequencing kits for variant detection in circulating cell-free DNA.Scientific reports · 2020Article
- Artificial Intelligence and Personalized Medicine.Cancer treatment and research · 2019Article
- Cancer Informatics in 2017: A New Beginning and a Bright Future.Yearbook of medical informatics · 2018Article
- Multiomics profiling of paired primary and recurrent glioblastoma patient tissues.Neuro-oncology advancesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe aim is to provide a comprehensive review of state-of-the art omics approaches, including proteomics, metabolomics, cell-free DNA, and patient cohort matching algorithms in precision oncology.
methodsIn the past several years, the cancer informatics revolution has been the beneficiary of a data explosion. Different complementary omics technologies have begun coming into their own to provide a more nuanced view of the patient-tumor interaction beyond that of DNA alterations. A combined approach is beneficial to the patient as nearly all new cancer therapeutics are designed with an omics biomarker in mind. Proteomics and metabolomics provide us with a means of assaying in real-time the response of the tumor to treatment. Circulating cell-free DNA may allow us to better understand tumor heterogeneity and interactions with the host genome.
resultsIntegration of increasingly available omics data increases our ability to segment patients into smaller and smaller cohorts, thereby prompting a shift in our thinking about how to use these omics data. With large repositories of patient omics-outcomes data being generated, patient cohort matching algorithms have become a dominant player.
conclusionsThe continued promise of precision oncology is to select patients who are most likely to benefit from treatment and to avoid toxicity for those who will not. The increased public availability of omics and outcomes data in patients, along with improved computational methods and resources, are making precision oncology a reality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.